Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase NA 1

Status

Recruiting 6Not yet recruiting 5Unknown 2Completed 2

Sponsor Class

OTHER 5

Study Type

Interventional 4Observational 1

Sponsor

Cancer Type

Breast 5

Conditions

Breast Neoplasms 11HER2-positive Breast Cancer 5Rare Tumour 1Metastatic Breast Cancer in the Brain 1Carcinoma, Non-Small-Cell Lung 1Advanced Digestive System Tumor 1

Interventions

pyrotinib 5Trastuzumab 4pertuzumab 2neratinib 1exemestane 1dalpiciclib 1Paclitaxel 1Leuprolide 1Goserelin 1Fulvestrant 1Docetaxel 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Not yet recruiting × HER2-positive Breast Cancer × pyrotinib × Clear all
NCT07470203 2026-03-13

Pyrotinib Combined With Trastuzumab and Pertuzumab for Maintenance Therapy in HER2-Positive Advanced Breast Cancer

Peking University Cancer Hospital & Institute

Not yet recruiting
42 enrolled
Breast

HER2-positive Breast Cancer

NCT07179939 2025-09-18

Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study

Fudan University

Phase 2 Not yet recruiting
288 enrolled
Breast

HER2-positive Breast Cancer

NCT06973525 2025-08-05

HER2-DM-NACT

Hebei Medical University Fourth Hospital

Phase 2 Not yet recruiting
30 enrolled
Breast

HER2-positive Breast Cancer

NCT06718335 2024-12-11

Pyrotinib in HER2-positive Early Breast Cancer

Yunnan Cancer Hospital

Phase NA Not yet recruiting
156 enrolled
Breast

HER2-positive Breast Cancer

NCT04158856 2019-11-12

SHERO

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 2 Not yet recruiting
60 enrolled
Breast

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡